Abstract
The aim of reproductive medicine is to support the birth of healthy children. Advances in assisted reproductive technologies and genetic analysis have led to the introduction of preimplantation genetic diagnosis (PGD) for embryos. Indications for PGD have been a major topic in the fields of ethics and law. Concerns vary by nation, religion, population, and segment, and the continued rapid development of new technologies. In contrast to the ethical augment, technology has been developing at an excessively rapid speed. The most significant recent technological development provides the ability to perform whole genome amplification and sequencing of single embryonic cells by microarray or next-generation sequencing methods. As new affordable technologies are introduced, patients are presented with a growing variety of PGD options. Simultaneously, the ethical guidelines for the indications for testing and handling of genetic information must also rapidly correspond to the changes.
Original language | English |
---|---|
Pages (from-to) | 69-75 |
Number of pages | 7 |
Journal | Reproductive Medicine and Biology |
Volume | 15 |
Issue number | 2 |
DOIs | |
Publication status | Published - 2016 Apr |
Keywords
- Microarray
- Polymerase chain reaction (PCR)
- Preimplantation genetic diagnosis (PGD)
- Preimplantation genetic screening (PGS)
- Whole genome amplification
ASJC Scopus subject areas
- Reproductive Medicine
- Cell Biology